{"id":45256,"date":"2022-06-20T14:01:38","date_gmt":"2022-06-20T12:01:38","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/edgewise-therapeutics-announces-positive-2-month-interim-results-from-the-arch-open-label-study-of-edg-5506-in-adults-with-becker-muscular-dystrophy-bmd\/"},"modified":"2022-06-20T14:01:38","modified_gmt":"2022-06-20T12:01:38","slug":"edgewise-therapeutics-announces-positive-2-month-interim-results-from-the-arch-open-label-study-of-edg-5506-in-adults-with-becker-muscular-dystrophy-bmd","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/edgewise-therapeutics-announces-positive-2-month-interim-results-from-the-arch-open-label-study-of-edg-5506-in-adults-with-becker-muscular-dystrophy-bmd\/","title":{"rendered":"Edgewise Therapeutics Announces Positive 2-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)"},"content":{"rendered":"
\n

\n\u2013 EDG-5506 treatment significantly<\/i> lowered muscle damage biomarkers in adults with BMD <\/i>\u2013<\/i>\n<\/p>\n

\n\u2013 <\/i>BMD patients were more active during 2 months of dosing with EDG-5506 relative to activity measured in BMD patients in the Phase 1 study <\/i>\u2013<\/i>\n<\/p>\n

\n\u2013 <\/i>EDG-5506 was well tolerated with no serious adverse events observed; s<\/i>afety profile supported dose escalation to 15 mg daily for all patients \u2013<\/i>\n<\/p>\n

\n\u2013 Management hosting webcast to discuss findings on June 21 at 9:00 a.m. Eastern Time \u2013<\/i>\n<\/p>\n

BOULDER, Colo.–(BUSINESS WIRE)–Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today positive 2-month interim results from the ongoing ARCH study, an open label, single-center study assessing the safety, tolerability, impact on muscle damage biomarkers, and pharmacokinetics (PK) of EDG-5506 in adults with BMD. EDG-5506 is an orally administered small molecule myosin inhibitor designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies such as Duchenne muscular dystrophy (DMD) and BMD.\n<\/p>\n

<\/a><\/p>\n

\nThe twelve adults with BMD enrolled in the ARCH study, including all seven participants from the Phase 1b study, were administered daily 10 mg oral doses of EDG-5506 at night. EDG-5506 was well-tolerated with no discontinuations or dose reductions. The most common adverse events observed at the 10 mg dose were dizziness (17%) and somnolence (17%). These were generally transient and typically observed in the first few days of dosing. All patients have subsequently been dose escalated to 15 mg daily as per protocol.\n<\/p>\n

\nThe 2-month plasma PK data for the 10 mg once-daily dose of EDG-5506 showed exposure levels that were approximately 61% of what was observed in the Phase 1b study where BMD participants were dosed with 20 mg EDG-5506 once-daily for two weeks. The reduced exposure for BMD participants in the ARCH study is consistent with the lower dose of 10 mg and a shorter half-life of EDG-5506 in BMD patients, likely associated with a decreased overall muscle mass.\n<\/p>\n

\nTreatment with EDG-5506 led to a significant decrease in key biomarkers of muscle damage when assessed by laboratory assays. Importantly, creatine kinase (CK) and fast skeletal muscle troponin I (TNNI2) were reduced by an average of 30% and 68%, respectively, after 2 months.\n<\/p>\n

\nBMD participants in the ARCH study were fitted with a pedometer to measure daily activity during waking hours. Activity levels at 2 months of dosing with EDG-5506 increased over both activity levels at 1 month and activity levels observed in participants in the Phase 1b study, even with lower overall exposure to EDG-5506.\n<\/p>\n

\nThe observation that both CK and TNNI2 were significantly decreased in the context of typical everyday activity levels is encouraging. The Company believes the 2-month ARCH study data provide further support for the hypothesis that EDG-5506 meaningfully reduces damage from the excessive stress present in dystrophic muscle, thus potentially preserving muscle function and preventing disease progression in dystrophinopathies.\n<\/p>\n

\n\u201cThe magnitude of reduction in biomarkers of muscle damage in adults with BMD is consistent with our observations in the Phase 1b trial,\u201d said Joanne Donovan, M.D., Ph.D., Chief Medical Officer of Edgewise. \u201cWe\u2019re encouraged by the decrease in biomarkers particularly in the context of the increased activity observed in BMD patients treated with EDG-5506.\u201d\n<\/p>\n

\n\u201cI want to express my deepest appreciation to the individuals with BMD who are participating in the EDG-5506 clinical trials,\u201d added Kevin Koch, Ph.D., President and Chief Executive Officer of Edgewise. \u201cThese interim 2-month ARCH data are promising, and we look forward to sharing further updates after patients have been dosed for 6 months.\u201d\n<\/p>\n

\nData Review Conference Call<\/b>\n<\/p>\n

\nMembers of the Edgewise management team will hold a conference call and webcast on Tuesday, June 21, at 9:00 am ET<\/b> to discuss the ARCH interim data. To participate, please dial 844-200-6205<\/b> (domestic) or 646-904-5544<\/b> (international) and refer to access code 260476<\/b>. Visit the Edgewise events<\/a> page to access the webcast, including replay and conference call slides.\n<\/p>\n

\nAbout the ARCH Open Label Study<\/b>\n<\/p>\n

\nThe ARCH open label study is evaluating EDG-5506 in 12 adult males with BMD. All those who participated in the Phase 1b first-in-human study of EDG-5506 enrolled in the ARCH study after at least a 3-month washout following their participation in the Phase 1b trial. The study is evaluating escalating doses of EDG-5506 administered daily over 12 months. Safety, pharmacokinetics (PK), changes in biomarkers of muscle damage such as creatine kinase (CK) and fast skeletal muscle troponin I (TNNI2), measures of function with North Star Ambulatory Assessment \/ North Star Assessment for Limb Girdle Type Muscular Dystrophies (NSAA\/NSAD), time function tests and patient-reported outcomes, are being evaluated. Go to clinicaltrials.gov to learn more about this study (NCT05160415<\/a>).\n<\/p>\n

\nAbout Becker Muscular Dystrophy<\/b>\n<\/p>\n

\nBMD is a serious, progressively debilitating, and potentially fatal inherited X-linked neuromuscular disorder. BMD results from mutation of the dystrophin gene yielding unstable and\/or dysfunctional dystrophin expression in muscles. Individuals with BMD, typically males, have ongoing muscle fiber (myofiber) degeneration that eventually leads to fibrosis, progressive loss of skeletal muscle function, and that can lead to severe disability and early death. BMD typically presents with juvenile onset of muscle wasting and progressive symmetrical, proximal muscle weakness, calf hypertrophy, activity-induced muscle cramping and elevated creatine kinase activity. While the course of BMD is variable, it is unidirectional in terms of the inevitable progressive limb weakness resulting in severe disability. BMD is also associated with early mortality from cardiac disease. The incidence of BMD is approximately 1 in every 18,450 live male births. It is estimated that there are between 4,000 to 5,000 individuals with BMD in the U.S., with similar numbers of individuals living with BMD in Europe. Despite the seriousness of the disease, for many with BMD, the disease remains one of considerable unmet medical need as there are no approved therapies in the U.S.\n<\/p>\n

\nAbout EDG-5506 for DMD and BMD<\/b>\n<\/p>\n

\nEDG-5506 is an orally administered small molecule designed to address muscle damage induced by mechanical stress in dystrophinopathies including DMD and BMD. EDG-5506 presents a novel mechanism of action to selectively limit the exaggerated muscle damage caused by the absence of functional dystrophin. EDG-5506 has the potential to benefit a broad range of patients suffering from debilitating rare neuromuscular disorders. It is anticipated to be used as a single agent therapy, but it may also provide a synergistic or additive effect in combination with available therapies and therapies currently in development. In August 2021, the U.S. Food and Drug Administration granted Fast Track designation to EDG-5506 for the treatment of individuals with BMD.\n<\/p>\n

\nThe Company has completed a Phase 1 clinical trial of EDG-5506 designed to evaluate safety, tolerability, PK and PD of EDG-5506 in adult healthy volunteers (Phase 1a) and in adults with BMD (Phase 1b). Go to clinicaltrials.gov to learn more about this clinical trial (NCT04585464<\/a>). A follow-on open-label, single-center study is assessing the long-term safety and PK of EDG-5506 in adults with BMD (NCT05160415<\/a>). The Company anticipates initiation of Phase 2 trials in individuals with BMD in the coming weeks and DMD in the second half of 2022.\n<\/p>\n

\nAbout Edgewise Therapeutics<\/b>\n<\/p>\n

\nEdgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare neuromuscular and cardiac disorders for which there is significant unmet medical need. Guided by its holistic drug discovery approach to targeting the muscle as an organ, Edgewise has combined its foundational expertise in muscle biology and small molecule engineering to build its proprietary, muscle-focused drug discovery platform. Edgewise\u2019s platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue. <\/b>To learn more, go to: www.edgewisetx.com<\/a> or follow us on LinkedIn<\/a>, Twitter<\/a> and Facebook<\/a>.\n<\/p>\n

\nCautionary Note Regarding Forward-Looking Statements<\/b>\n<\/p>\n

\nThis press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the potential of, and expectations regarding, Edgewise\u2019s drug discovery platform, product candidates and programs, including EDG-5506; statements regarding Edgewise’s expectations relating to its clinical trials of EDG-5506, including the timing of the initiation of Phase 2 trials in individuals with BMD and DMD and the timing of sharing further updates from the ARCH study; statements by Edgewise’s president and chief executive officer and chief medical officer. Words such as \u201cbelieves,\u201d \u201canticipates,\u201d \u201cplans,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201cwill,\u201d \u201cgoal,\u201d \u201cpotential\u201d and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon Edgewise\u2019s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward-looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early clinical stage company including the potential for Edgewise\u2019s product candidates to cause serious adverse events; Edgewise\u2019s ability to develop, initiate or complete preclinical studies and clinical trials for, obtain approvals for and commercialize any of its product candidates for muscular dystrophy patients or other patient populations; the timing, progress and results of preclinical studies and clinical trials for EDG-5506; Edgewise\u2019s ability to raise any additional funding it will need to continue to pursue its business and product development plans; negative impacts of the COVID-19 pandemic on Edgewise\u2019s operations, including preclinical and clinical trials; the timing, scope and likelihood of regulatory filings and approvals; the potential for any clinical trial results to differ from preclinical, interim, preliminary, topline or expected results; Edgewise\u2019s ability to develop a proprietary drug discovery platform to build a pipeline of product candidates; Edgewise\u2019s ability to enroll and maintain patients in its ongoing and future clinical trials; Edgewise\u2019s manufacturing, commercialization and marketing capabilities and strategy; the size of the market opportunity for Edgewise\u2019s product candidates; the loss of key scientific or management personnel; competition in the industry in which Edgewise operates; Edgewise\u2019s reliance on third parties; Edgewise\u2019s ability to obtain and maintain intellectual property protection for its product candidates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled \u201cRisk Factors\u201d in documents that Edgewise files from time to time with the Securities and Exchange Commission. These forward-looking statements are made as of the date of this press release, and Edgewise assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.<\/b>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestors & Media<\/b>
Michael Carruthers
\n
Chief Financial Officer
\n
IR@edgewisetx.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

\u2013 EDG-5506 treatment significantly lowered muscle damage biomarkers in adults with BMD \u2013 \u2013 BMD patients were more active during 2 months of dosing with EDG-5506 relative to activity measured in BMD patients in the Phase 1 study \u2013 \u2013 EDG-5506 was well tolerated with no serious adverse events observed; safety profile supported dose escalation … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-45256","6":"format-standard","7":"category-industry"},"yoast_head":"\nEdgewise Therapeutics Announces Positive 2-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD) - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/edgewise-therapeutics-announces-positive-2-month-interim-results-from-the-arch-open-label-study-of-edg-5506-in-adults-with-becker-muscular-dystrophy-bmd\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Edgewise Therapeutics Announces Positive 2-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD) - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"\u2013 EDG-5506 treatment significantly lowered muscle damage biomarkers in adults with BMD \u2013 \u2013 BMD patients were more active during 2 months of dosing with EDG-5506 relative to activity measured in BMD patients in the Phase 1 study \u2013 \u2013 EDG-5506 was well tolerated with no serious adverse events observed; safety profile supported dose escalation ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/edgewise-therapeutics-announces-positive-2-month-interim-results-from-the-arch-open-label-study-of-edg-5506-in-adults-with-becker-muscular-dystrophy-bmd\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-20T12:01:38+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220620005099\/en\/1382019\/21\/Edgewise-Logo_FINAL.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/edgewise-therapeutics-announces-positive-2-month-interim-results-from-the-arch-open-label-study-of-edg-5506-in-adults-with-becker-muscular-dystrophy-bmd\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/edgewise-therapeutics-announces-positive-2-month-interim-results-from-the-arch-open-label-study-of-edg-5506-in-adults-with-becker-muscular-dystrophy-bmd\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Edgewise Therapeutics Announces Positive 2-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)\",\"datePublished\":\"2022-06-20T12:01:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/edgewise-therapeutics-announces-positive-2-month-interim-results-from-the-arch-open-label-study-of-edg-5506-in-adults-with-becker-muscular-dystrophy-bmd\\\/\"},\"wordCount\":1811,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/edgewise-therapeutics-announces-positive-2-month-interim-results-from-the-arch-open-label-study-of-edg-5506-in-adults-with-becker-muscular-dystrophy-bmd\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220620005099\\\/en\\\/1382019\\\/21\\\/Edgewise-Logo_FINAL.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/edgewise-therapeutics-announces-positive-2-month-interim-results-from-the-arch-open-label-study-of-edg-5506-in-adults-with-becker-muscular-dystrophy-bmd\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/edgewise-therapeutics-announces-positive-2-month-interim-results-from-the-arch-open-label-study-of-edg-5506-in-adults-with-becker-muscular-dystrophy-bmd\\\/\",\"name\":\"Edgewise Therapeutics Announces Positive 2-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD) - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/edgewise-therapeutics-announces-positive-2-month-interim-results-from-the-arch-open-label-study-of-edg-5506-in-adults-with-becker-muscular-dystrophy-bmd\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/edgewise-therapeutics-announces-positive-2-month-interim-results-from-the-arch-open-label-study-of-edg-5506-in-adults-with-becker-muscular-dystrophy-bmd\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220620005099\\\/en\\\/1382019\\\/21\\\/Edgewise-Logo_FINAL.jpg\",\"datePublished\":\"2022-06-20T12:01:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/edgewise-therapeutics-announces-positive-2-month-interim-results-from-the-arch-open-label-study-of-edg-5506-in-adults-with-becker-muscular-dystrophy-bmd\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/edgewise-therapeutics-announces-positive-2-month-interim-results-from-the-arch-open-label-study-of-edg-5506-in-adults-with-becker-muscular-dystrophy-bmd\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/edgewise-therapeutics-announces-positive-2-month-interim-results-from-the-arch-open-label-study-of-edg-5506-in-adults-with-becker-muscular-dystrophy-bmd\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220620005099\\\/en\\\/1382019\\\/21\\\/Edgewise-Logo_FINAL.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220620005099\\\/en\\\/1382019\\\/21\\\/Edgewise-Logo_FINAL.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/edgewise-therapeutics-announces-positive-2-month-interim-results-from-the-arch-open-label-study-of-edg-5506-in-adults-with-becker-muscular-dystrophy-bmd\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Edgewise Therapeutics Announces Positive 2-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Edgewise Therapeutics Announces Positive 2-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD) - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/edgewise-therapeutics-announces-positive-2-month-interim-results-from-the-arch-open-label-study-of-edg-5506-in-adults-with-becker-muscular-dystrophy-bmd\/","og_locale":"en_US","og_type":"article","og_title":"Edgewise Therapeutics Announces Positive 2-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD) - Pharma Trend","og_description":"\u2013 EDG-5506 treatment significantly lowered muscle damage biomarkers in adults with BMD \u2013 \u2013 BMD patients were more active during 2 months of dosing with EDG-5506 relative to activity measured in BMD patients in the Phase 1 study \u2013 \u2013 EDG-5506 was well tolerated with no serious adverse events observed; safety profile supported dose escalation ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/edgewise-therapeutics-announces-positive-2-month-interim-results-from-the-arch-open-label-study-of-edg-5506-in-adults-with-becker-muscular-dystrophy-bmd\/","og_site_name":"Pharma Trend","article_published_time":"2022-06-20T12:01:38+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220620005099\/en\/1382019\/21\/Edgewise-Logo_FINAL.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/edgewise-therapeutics-announces-positive-2-month-interim-results-from-the-arch-open-label-study-of-edg-5506-in-adults-with-becker-muscular-dystrophy-bmd\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/edgewise-therapeutics-announces-positive-2-month-interim-results-from-the-arch-open-label-study-of-edg-5506-in-adults-with-becker-muscular-dystrophy-bmd\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Edgewise Therapeutics Announces Positive 2-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)","datePublished":"2022-06-20T12:01:38+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/edgewise-therapeutics-announces-positive-2-month-interim-results-from-the-arch-open-label-study-of-edg-5506-in-adults-with-becker-muscular-dystrophy-bmd\/"},"wordCount":1811,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/edgewise-therapeutics-announces-positive-2-month-interim-results-from-the-arch-open-label-study-of-edg-5506-in-adults-with-becker-muscular-dystrophy-bmd\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220620005099\/en\/1382019\/21\/Edgewise-Logo_FINAL.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/edgewise-therapeutics-announces-positive-2-month-interim-results-from-the-arch-open-label-study-of-edg-5506-in-adults-with-becker-muscular-dystrophy-bmd\/","url":"https:\/\/pharma-trend.com\/en\/edgewise-therapeutics-announces-positive-2-month-interim-results-from-the-arch-open-label-study-of-edg-5506-in-adults-with-becker-muscular-dystrophy-bmd\/","name":"Edgewise Therapeutics Announces Positive 2-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD) - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/edgewise-therapeutics-announces-positive-2-month-interim-results-from-the-arch-open-label-study-of-edg-5506-in-adults-with-becker-muscular-dystrophy-bmd\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/edgewise-therapeutics-announces-positive-2-month-interim-results-from-the-arch-open-label-study-of-edg-5506-in-adults-with-becker-muscular-dystrophy-bmd\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220620005099\/en\/1382019\/21\/Edgewise-Logo_FINAL.jpg","datePublished":"2022-06-20T12:01:38+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/edgewise-therapeutics-announces-positive-2-month-interim-results-from-the-arch-open-label-study-of-edg-5506-in-adults-with-becker-muscular-dystrophy-bmd\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/edgewise-therapeutics-announces-positive-2-month-interim-results-from-the-arch-open-label-study-of-edg-5506-in-adults-with-becker-muscular-dystrophy-bmd\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/edgewise-therapeutics-announces-positive-2-month-interim-results-from-the-arch-open-label-study-of-edg-5506-in-adults-with-becker-muscular-dystrophy-bmd\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220620005099\/en\/1382019\/21\/Edgewise-Logo_FINAL.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220620005099\/en\/1382019\/21\/Edgewise-Logo_FINAL.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/edgewise-therapeutics-announces-positive-2-month-interim-results-from-the-arch-open-label-study-of-edg-5506-in-adults-with-becker-muscular-dystrophy-bmd\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Edgewise Therapeutics Announces Positive 2-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD)"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45256","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=45256"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/45256\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=45256"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=45256"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=45256"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}